Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
Frequently asked questions
What sector does Deciphera Pharmaceuticals, Inc (DCPH) operate in?
Deciphera Pharmaceuticals, Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Deciphera Pharmaceuticals, Inc (DCPH) Earnings Per Share (EPS)?
The trailing EPS is -$2.21, and the forward EPS is -$1.68.
What is Deciphera Pharmaceuticals, Inc (DCPH) EBITDA?
Deciphera Pharmaceuticals, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -47.25 million.
Does Deciphera Pharmaceuticals, Inc (DCPH) pay dividends?
No. Deciphera Pharmaceuticals, Inc does not pay a dividend.
How did Deciphera Pharmaceuticals, Inc (DCPH) perform in its most recent earnings report?
In the last report (March 31, 2024), Deciphera Pharmaceuticals, Inc posted an EPS surprise of 5.45% and a revenue surprise of -2.77%.
When is Deciphera Pharmaceuticals, Inc (DCPH) next earnings report?
Deciphera Pharmaceuticals, Inc is expected to release its next earnings report on June 30, 2024.
